EXHIBIT 31.2

                                  CERTIFICATION

I, Simcha Edell, certify the following:

      7.    I have reviewed this quarterly report on Form 10-QSB of Amazon
            Biotech, Inc.;

      8.    Based on my knowledge, this quarterly report does not contain any
            untrue statement of a material fact or omit to state a material fact
            necessary to make the statements made, in light of the circumstances
            under which such statements were made, not misleading with respect
            to the period covered by this quarterly report;

      9.    Based on my knowledge, the financial statements, and other financial
            information included in this quarterly report, fairly present in all
            material respects the financial condition, results of operations and
            cash flows of Amazon Biotech, Inc. as of, and for, the periods
            presented in this quarterly report;

      10.   Amazon Biotech, Inc.'s other certifying officer and I are
            responsible for establishing and maintaining disclosure controls and
            procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for
            Amazon Biotech, Inc. and we have done the following:

            a.    designed such disclosure controls and procedures to ensure
                  that material information relating to Amazon Biotech, Inc. is
                  made known to us by others within the Company, particularly
                  during the period in which this quarterly report is being
                  prepared;

            b.    evaluated the effectiveness of Amazon Biotech, Inc.'s
                  disclosure controls and procedures as of a date within 90 days
                  prior to the filing date of this quarterly report (the
                  "Evaluation Date"); and

            c.    presented in this quarterly report our conclusions about the
                  effectiveness of the disclosure controls and procedures based
                  on our evaluation as of the Evaluation Date;

      11.   Amazon Biotech, Inc.'s other certifying officer and I have
            disclosed, based on our most recent evaluation, to Amazon Biotech,
            Inc.'s auditors and the audit committee of Amazon Biotech Inc.'s
            board of directors:

            a.    all significant deficiencies in the design or operation of
                  internal controls which could adversely affect Amazon Biotech,
                  Inc.'s ability to record, process, summarize and report
                  financial data and have identified for Amazon Biotech, Inc.'s
                  auditors any material weaknesses in internal controls; and

            b.    any fraud, whether or not material, that involves management
                  or other employees who have a significant role in Amazon
                  Biotech, Inc.'s internal controls; and

      12.   Amazon Biotech, Inc.'s other certifying officer and I have indicated
            in this quarterly report whether or not there were significant
            changes in internal controls or in other factors that could
            significantly affect internal controls subsequent to the date of our
            most recent evaluation, including any corrective actions with regard
            to significant deficiencies and material weaknesses.

March 22, 2006                      /s/ Simcha Edell
                                    ----------------------------------------
                                    Simcha Edell
                                    Chief Financial Officer
                                    (Principal Financial and Accounting Officer)